Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Futami, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Futami, H
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology Pages 588-589

Guest Editorial

Guest Editorial

DNA TESTING FOR MORE SOPHISTICATED CLINICAL MANAGEMENT OF MULTIPLE ENDOCRINE NEOPLASMA TYPE 2 (MEN 2)

DNA testing to predict cancer predisposition currently plays an important role in the clinical management of hereditary cancer. MEN 2 syndromes are autosomal dominant inherited cancer syndromes, and DNA testing is now useful in clinical practice of these diseases. MEN 2 syndromes are subclassified into MEN 2A, MEN 2B, and familial medullary thyroid carcinoma (FMTC). MEN 2A is characterized by the development of medullary thyroid carcinoma (MTC), pheochromocytoma and hyperparathyroidism (HPT). MEN 2B is also associated with MTC and pheochromocytoma but has developmental abnormalities such as marfanoid habitus, mucosal neuromas and ganglioneuromatosis. In FMTC, MTC is the only disease feature. Recently, the RET proto-oncogene has been identified as the susceptibility gene for MEN 2 (1-3). The gene encodes a receptor tyrosine kinase and its physiological ligands are glial-cell-line-derived neurotropic factor (GDNF) . . . [Full Text of this Article]

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?